BALA CYNWYD, Pa., Jan. 04, 2024 (GLOBE NEWSWIRE) -- Brodsky & Smith reminds investors of the following investigations. If you own shares and wish to discuss the investigation, contact Jason Brodsky (jbrodsky@brodskysmith.com) or Marc Ackerman (mackerman@brodskysmith.com) at 855-576-4847. There is no cost or financial obligation to you.
RayzeBio, Inc. (Nasdaq – RYZB)
Under the terms of the agreement, RayzeBio will be acquired by Bristol Myers Squibb (NYSE: BMY) in an all-cash transaction valued at approximately $4.1 billion. Under the terms of the agreement, RayzeBio stockholders will receive $62.50 per share in cash upon completion of the proposed transaction. The investigation concerns whether the RayzeBio Board breached its fiduciary duties to shareholders by failing to conduct a fair process, including whether Bristol Myers Squibb is paying fair value to shareholders of the Company.
Additional information can be found at https://www.brodskysmith.com/cases/rayzebio-inc-nasdaq-ryzb.
Gracell Biotechnologies Inc. (Nasdaq – GRCL)
Under the terms of the agreement, Gracell will be acquired by AstraZeneca PLC (Nasdaq - AZN), which will acquire all of Gracell’s fully diluted share capital (including shares represented by ADSs) through a merger for a price of $2.00 per ordinary share in cash at closing (equivalent to $10.00 per ADS of Gracell) plus a non-tradable contingent value right of $0.30 per ordinary share (equivalent to $1.50 per ADS of Gracell) in cash payable upon achievement of a specified regulatory milestone. The investigation concerns whether the Gracell Board breached its fiduciary duties to shareholders by failing to conduct a fair process, including whether AstraZeneca PLC is paying fair value to shareholders of the Company.
Additional information can be found at https://www.brodskysmith.com/cases/gracell-biotechnologies-inc-nasdaq-grcl/.
Daseke, Inc. (Nasdaq – DSKE)
Under the terms of the agreement, Daseke will be acquired by TFI International Inc. (“TFI International”) (NYSE - TFII) in an all-cash transaction valued at approximately $1.1 billion. Daseke shareholders will receive $8.30 per share in cash for each share held. The investigation concerns whether the Daseke Board breached its fiduciary duties to shareholders by failing to conduct a fair process, including whether TFI International is paying fair value to shareholders of the Company.
Additional information can be found at https://www.brodskysmith.com/cases/daseke-inc-nasdaq-dske/.
Karuna Therapeutics, Inc. (Nasdaq – KRTX)
Under the terms of the Merger Agreement, Karuna Therapeutics will be acquired by Bristol Myers Squibb (NYSE: BMY) in an all-cash transaction valued at approximately $14 billion. Karuna Therapeutics stockholders will receive $330.00 per share in cash upon completion of the proposed transaction. The investigation concerns whether the Karuna Therapeutics Board breached its fiduciary duties to shareholders by failing to conduct a fair process, including whether Bristol Myers Squibb is paying fair value to shareholders of the Company.
Additional information can be found at https://www.brodskysmith.com/cases/karuna-therapeutics-inc-nasdaq-krtx/.
Brodsky & Smith is a litigation law firm with extensive expertise representing shareholders throughout the nation in securities and class action lawsuits. The attorneys at Brodsky & Smith have been appointed by numerous courts throughout the country to serve as lead counsel in class actions and have successfully recovered millions of dollars for our clients and shareholders. Attorney advertising. Prior results do not guarantee a similar outcome.
